Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 10/20 | 0.49 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 3/20 | 0.41 |
| ▸ | PYGM | P11217 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484208 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL28379664 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL15284881 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL29406981 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL31598843 | 0.83 | PYGB (0.43) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL30569120 | 0.83 | PYGB (0.43) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL11505360 | 0.83 | PYGB (0.52) | PYGBPYGLPYGM | |
| SCHEMBL9221292 | 0.81 | PYGB (0.48) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL10357870 | 0.81 | PYGB (0.51) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL30381206 | 0.80 | PYGB (0.43) | PYGBPYGLPYGMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8277304-A | — | — | None | — | — | JP | disclosed |
| WO-2025132301-A1 | METHOD FOR PREPARING AN AERATED FROZEN PRODUCT | STANDING OVATION (FR) | 2025-06-26 | — | — | WO | disclosed |
| EP-4573922-A1 | METHOD FOR PREPARING AN AERATED FROZEN PRODUCT | Standing Ovation (FR) | 2025-06-25 | — | — | EP | disclosed |
| WO-2023192711-A1 | COMPOSITIONS AND METHODS FOR DELIVERING BIOACTIVE AGENTS | Perfect Day, Inc. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-4192850-A1 | FUSION PROTEINS COMPRISING MILK PROTEINS AND COMPOSITIONS THEREOF | Perfect Day, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4106534-A2 | HYPOALLERGENIC RECOMBINANT MILK PROTEINS AND COMPOSITIONS COMPRISING THE SAME | Perfect Day, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20110086767-A1 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | INSTITUT PASTEUR | 2011-04-14 | — | — | US | disclosed |
| EP-2100965-A1 | Mutants of glycoside hydrolases and uses thereof for synthesizing complex oligosaccharides and disaccharide intermediates | Institut Pasteur (FR) | 2009-09-16 | — | — | EP | disclosed |
| US-20030170828-A1 | Synthesis of complex carbohydrates | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-09-11 | — | — | US | disclosed |
| EP-1311550-A2 | SYNTHESIS OF COMPLEX CARBOHYDRATES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016438-A2 | SYNTHESIS OF COMPLEX CARBOHYDRATES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-02-28 | — | — | WO | disclosed |
| US-5741783-A | TREATING CHITOSAN WITH FORMALDEHYDE AND HYDROGEN CYANIDE YIELDS MIXTURES FOR USE IN FILMS AND MEMBRANES, WATER TREATMENT, COMPLEXING AGENTS, STABILIZERS AND COSMETICS | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-04-21 | — | — | US | disclosed |
| JP-H08277304-A | N-CYANOMETHYLATED CHITOSAN AND HYDROLYSATE THEREOF | CIBA GEIGY AG | 1996-10-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086767-A1 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | ENGASE, GALE, MGAM | PYGB 822/4885OGA 32/4885PYGL 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.